Nöromüsküler Kas Hastalıkları
Özet
Nöromüsküler hastalıklar (NMH), periferik sinir sistemi ve kasları etkileyen, sıklıkla solunum disfonksiyonuna neden olan patolojilerdir. Yoğun bakım ünitesi (YBÜ), özellikler akut alevlenmeler veya ilerleyici hastalık evreleri sırasında önemli bir rol oynar. Bu derlemede, NMH ve YBÜ kesişimini araştırarak tanı, solunum desteği ve multidisipliner tedavi yaklaşımlarını ele alınmıştır.
Neuromuscular diseases encompass various conditions affecting the muscles and their direct nervous system control, often leading to severe respiratory and motor function impairments. The intensive care unit (ICU) is crucial in managing NMD patients, particularly during acute exacerbations or progressive disease stages. This review explores the intersection of NMD and ICU care, highlighting the complexities of diagnosis, respiratory support, and multidisciplinary treatment approaches.
Referanslar
Alshekhlee A, Hussain Z, Sultan B, Katirji B. Guillain–Barré syndrome: incidence and mortality rates in US hospitals. Neurology. 2008;70(18):1608-13.
Longo DL. Nils E. Gilhus, MD. N Engl J Med. 2016;375:2570-81.
Bradley W, RB Daroff, Fenichel G, Jankovic J. Neurology in Clinical Practice. The Neurological Disorders: Butterworth-Heinemann; 2004.
Kramer CL, Rabinstein AA. Neuromuscular Disease in the ICU. Evidence-Based Critical Care: A Case Study Approach. 2020:347-58.
Eelco F. M. Wijdicks M, PhD, James Y. Findlay M, ChB, William D. Freeman M, Ayan Sen M. Mayo Clinic Critical and Neurorocritical Care Board Review. 198 Madison Avenue, New York, NY 10016, United States of America.: Oxford University Press 2019.
Wijdicks E. The practice of emergency and critical care neurology. Short of breath. 2 ed. New York (NY): Oxford University Press; 2016. p. 76-81.
Damian MS, Wijdicks EF. The clinical management of neuromuscular disorders in intensive care. Neuromuscular Disorders. 2019;29(2):85-96.
Sarwal A, Walker FO, Cartwright MS. Neuromuscular ultrasound for evaluation of the diaphragm. Muscle & nerve. 2013;47(3):319-29.
Hughes RA, Cornblath DR. Guillain-barre syndrome. The Lancet. 2005;366(9497):1653-66.
Willison HJ, Jacobs BC, van Doorn PA. Guillain-barre syndrome. The Lancet. 2016;388(10045):717-27.
Tham SL, Prasad K, Umapathi T. Guillain–Barré syndrome mimics. Brain and Behavior. 2018;8(5):e00960.
Truax BT, editor Autonomic disturbances in the Guillain-Barré syndrome. Seminars in Neurology; 1984: © 1984 by Thieme Medical Publishers, Inc.
Gordon PH, Wilbourn AJ. Early electrodiagnostic findings in Guillain-Barré syndrome. Archives of neurology. 2001;58(6):913-7.
Van den Berg B, Walgaard C, Drenthen J, Fokke C, Jacobs BC, Van Doorn PA. Guillain–Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nature Reviews Neurology. 2014;10(8):469-82.
Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain‐Barré syndrome. Cochrane Database of Systematic Reviews. 2017(2).
Van der Meché F, Schmitz P, Group* DGBS. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain–Barré syndrome. New England Journal of Medicine. 1992;326(17):1123-9.
Doets AY, Hughes RA, Brassington R, Hadden RD, Pritchard J. Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain‐Barré syndrome. Cochrane Database of Systematic Reviews. 2020(1).
Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. The Lancet Neurology. 2015;14(10):1023-36.
Jaretzki A, Barohn R, Ernstoff R, Kaminski H, Keesey J, Penn A, et al. Myasthenia gravis: recommendations for clinical research standards. Neurology. 2000;55(1):16-23.
Conti-Fine BM, Milani M, Kaminski HJ. Myasthenia gravis: past, present, and future. The Journal of clinical investigation. 2006;116(11):2843-54.
Osserman KE, Kaplan LI. RAPID DIAGNOSTIC TEST FOR MYASTHENIA GRAVIS: INCREASED MUSCLE STRENGTH, WITHOUT FASCICULATIONS, AFTER INTRAVENOUS ADMINISTRATION OF EDROPHONIUM (TENSILON®) CHLORIDE. Journal of the American Medical Association. 1952;150(4):265-8.
Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. The Lancet Neurology. 2009;8(5):475-90.
Gilchrist JM, Massey JM, Sanders DB. Single fiber EMG and repetitive stimulation of the same muscle in myasthenia gravis. Muscle & Nerve: Official Journal of the American Association of Electrodiagnostic Medicine. 1994;17(2):171-5.
Stalberg E. Clinical electrophysiology in myasthenia gravis. Journal of Neurology, Neurosurgery & Psychiatry. 1980;43(7):622-33.
Moore AV, Korobkin M, Powers B, Olanow W, Ravin CE, Putman CE, et al. Thymoma detection by mediastinal CT: patient with myasthenia gravis. American Journal of Roentgenology. 1982;138(2):217-22.
Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I, et al. International consensus guidance for management of myasthenia gravis: executive summary. Neurology. 2016;87(4):419-25.
Rengin R, ZERAY C, SİPAHİ H. Clostridium Botulinum Kaynaklı Gıda Zehirlenmeleri: Botulizm. Hacettepe University Journal of the Faculty of Pharmacy. 2019;39(1):58-63.
Birinci Basamağa Yönelik Zehirlenmeler Tanı ve Tedavi Rehberleri. Türkiye: SB, RSHMB, Hıfzusıhha Mektebi Müdürlüğü; 2007. 153-7 p.
Vanholder R, Sever MS, Erek E, Lameire N. Rhabdomyolysis. Journal of the American Society of Nephrology. 2000;11(8):1553-61.
Zutt R, Van Der Kooi A, Linthorst G, Wanders R, De Visser M. Rhabdomyolysis: review of the literature. Neuromuscular Disorders. 2014;24(8):651-9.
Giannoglou GD, Chatzizisis YS, Misirli G. The syndrome of rhabdomyolysis: pathophysiology and diagnosis. European journal of internal medicine. 2007;18(2):90-100.
Tobon A. Metabolic myopathies. CONTINUUM: Lifelong Learning in Neurology. 2013;19(6):1571-97.
TOPÇUOĞLU MA. Yoğun Bakım Ünitelerinde Nöromusküler Güçsüzlüğe Yaklaşım.
Latronico N, Bolton CF. Critical illness polyneuropathy and myopathy: a major cause of muscle weakness and paralysis. The Lancet Neurology. 2011;10(10):931-41.
Latronico N, Bertolini G, Guarneri B, Botteri M, Peli E, Andreoletti S, et al. Simplified electrophysiological evaluation of peripheral nerves in critically ill patients: the Italian multi-centre CRIMYNE study. Critical Care. 2007;11:1-11.
Garnacho-Montero J, Amaya-Villar R, García-Garmendía JL, Madrazo-Osuna J, Ortiz-Leyba C. Effect of critical illness polyneuropathy on the withdrawal from mechanical ventilation and the length of stay in septic patients. Critical care medicine. 2005;33(2):349-54.
Bednarik J, Vondracek P, Dusek L, Moravcova E, Cundrle I. Risk factors for critical illness polyneuromyopathy. Journal of neurology. 2005;252:343-51.
Witt NJ, Zochodne DW, Bolton CF, Grand'Maison F, Wells G, Young GB, et al. Peripheral nerve function in sepsis and multiple organ failure. Chest. 1991;99(1):176-84.
Hermans G, Van den Berghe G. Clinical review: intensive care unit acquired weakness. Critical care. 2015;19(1):1-9.
Hermans G, De Jonghe B, Bruyninckx F, Berghe GVd. Clinical review: Critical illness polyneuropathy and myopathy. Critical care. 2008;12(6):1-9.
Guarneri B, Bertolini G, Latronico N. Long-term outcome in patients with critical illness myopathy or neuropathy: the Italian multicentre CRIMYNE study. Journal of Neurology, Neurosurgery & Psychiatry. 2008;79(7):838-41.
Bolton CF. Neuromuscular manifestations of critical illness. Muscle & Nerve: Official Journal of the American Association of Electrodiagnostic Medicine. 2005;32(2):140-63.
Lacomis D, Zochodne DW, Bird SJ. Critical illness myopathy. Wiley Online Library; 2000. p. 1785-8.
Referanslar
Alshekhlee A, Hussain Z, Sultan B, Katirji B. Guillain–Barré syndrome: incidence and mortality rates in US hospitals. Neurology. 2008;70(18):1608-13.
Longo DL. Nils E. Gilhus, MD. N Engl J Med. 2016;375:2570-81.
Bradley W, RB Daroff, Fenichel G, Jankovic J. Neurology in Clinical Practice. The Neurological Disorders: Butterworth-Heinemann; 2004.
Kramer CL, Rabinstein AA. Neuromuscular Disease in the ICU. Evidence-Based Critical Care: A Case Study Approach. 2020:347-58.
Eelco F. M. Wijdicks M, PhD, James Y. Findlay M, ChB, William D. Freeman M, Ayan Sen M. Mayo Clinic Critical and Neurorocritical Care Board Review. 198 Madison Avenue, New York, NY 10016, United States of America.: Oxford University Press 2019.
Wijdicks E. The practice of emergency and critical care neurology. Short of breath. 2 ed. New York (NY): Oxford University Press; 2016. p. 76-81.
Damian MS, Wijdicks EF. The clinical management of neuromuscular disorders in intensive care. Neuromuscular Disorders. 2019;29(2):85-96.
Sarwal A, Walker FO, Cartwright MS. Neuromuscular ultrasound for evaluation of the diaphragm. Muscle & nerve. 2013;47(3):319-29.
Hughes RA, Cornblath DR. Guillain-barre syndrome. The Lancet. 2005;366(9497):1653-66.
Willison HJ, Jacobs BC, van Doorn PA. Guillain-barre syndrome. The Lancet. 2016;388(10045):717-27.
Tham SL, Prasad K, Umapathi T. Guillain–Barré syndrome mimics. Brain and Behavior. 2018;8(5):e00960.
Truax BT, editor Autonomic disturbances in the Guillain-Barré syndrome. Seminars in Neurology; 1984: © 1984 by Thieme Medical Publishers, Inc.
Gordon PH, Wilbourn AJ. Early electrodiagnostic findings in Guillain-Barré syndrome. Archives of neurology. 2001;58(6):913-7.
Van den Berg B, Walgaard C, Drenthen J, Fokke C, Jacobs BC, Van Doorn PA. Guillain–Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nature Reviews Neurology. 2014;10(8):469-82.
Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain‐Barré syndrome. Cochrane Database of Systematic Reviews. 2017(2).
Van der Meché F, Schmitz P, Group* DGBS. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain–Barré syndrome. New England Journal of Medicine. 1992;326(17):1123-9.
Doets AY, Hughes RA, Brassington R, Hadden RD, Pritchard J. Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain‐Barré syndrome. Cochrane Database of Systematic Reviews. 2020(1).
Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. The Lancet Neurology. 2015;14(10):1023-36.
Jaretzki A, Barohn R, Ernstoff R, Kaminski H, Keesey J, Penn A, et al. Myasthenia gravis: recommendations for clinical research standards. Neurology. 2000;55(1):16-23.
Conti-Fine BM, Milani M, Kaminski HJ. Myasthenia gravis: past, present, and future. The Journal of clinical investigation. 2006;116(11):2843-54.
Osserman KE, Kaplan LI. RAPID DIAGNOSTIC TEST FOR MYASTHENIA GRAVIS: INCREASED MUSCLE STRENGTH, WITHOUT FASCICULATIONS, AFTER INTRAVENOUS ADMINISTRATION OF EDROPHONIUM (TENSILON®) CHLORIDE. Journal of the American Medical Association. 1952;150(4):265-8.
Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. The Lancet Neurology. 2009;8(5):475-90.
Gilchrist JM, Massey JM, Sanders DB. Single fiber EMG and repetitive stimulation of the same muscle in myasthenia gravis. Muscle & Nerve: Official Journal of the American Association of Electrodiagnostic Medicine. 1994;17(2):171-5.
Stalberg E. Clinical electrophysiology in myasthenia gravis. Journal of Neurology, Neurosurgery & Psychiatry. 1980;43(7):622-33.
Moore AV, Korobkin M, Powers B, Olanow W, Ravin CE, Putman CE, et al. Thymoma detection by mediastinal CT: patient with myasthenia gravis. American Journal of Roentgenology. 1982;138(2):217-22.
Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I, et al. International consensus guidance for management of myasthenia gravis: executive summary. Neurology. 2016;87(4):419-25.
Rengin R, ZERAY C, SİPAHİ H. Clostridium Botulinum Kaynaklı Gıda Zehirlenmeleri: Botulizm. Hacettepe University Journal of the Faculty of Pharmacy. 2019;39(1):58-63.
Birinci Basamağa Yönelik Zehirlenmeler Tanı ve Tedavi Rehberleri. Türkiye: SB, RSHMB, Hıfzusıhha Mektebi Müdürlüğü; 2007. 153-7 p.
Vanholder R, Sever MS, Erek E, Lameire N. Rhabdomyolysis. Journal of the American Society of Nephrology. 2000;11(8):1553-61.
Zutt R, Van Der Kooi A, Linthorst G, Wanders R, De Visser M. Rhabdomyolysis: review of the literature. Neuromuscular Disorders. 2014;24(8):651-9.
Giannoglou GD, Chatzizisis YS, Misirli G. The syndrome of rhabdomyolysis: pathophysiology and diagnosis. European journal of internal medicine. 2007;18(2):90-100.
Tobon A. Metabolic myopathies. CONTINUUM: Lifelong Learning in Neurology. 2013;19(6):1571-97.
TOPÇUOĞLU MA. Yoğun Bakım Ünitelerinde Nöromusküler Güçsüzlüğe Yaklaşım.
Latronico N, Bolton CF. Critical illness polyneuropathy and myopathy: a major cause of muscle weakness and paralysis. The Lancet Neurology. 2011;10(10):931-41.
Latronico N, Bertolini G, Guarneri B, Botteri M, Peli E, Andreoletti S, et al. Simplified electrophysiological evaluation of peripheral nerves in critically ill patients: the Italian multi-centre CRIMYNE study. Critical Care. 2007;11:1-11.
Garnacho-Montero J, Amaya-Villar R, García-Garmendía JL, Madrazo-Osuna J, Ortiz-Leyba C. Effect of critical illness polyneuropathy on the withdrawal from mechanical ventilation and the length of stay in septic patients. Critical care medicine. 2005;33(2):349-54.
Bednarik J, Vondracek P, Dusek L, Moravcova E, Cundrle I. Risk factors for critical illness polyneuromyopathy. Journal of neurology. 2005;252:343-51.
Witt NJ, Zochodne DW, Bolton CF, Grand'Maison F, Wells G, Young GB, et al. Peripheral nerve function in sepsis and multiple organ failure. Chest. 1991;99(1):176-84.
Hermans G, Van den Berghe G. Clinical review: intensive care unit acquired weakness. Critical care. 2015;19(1):1-9.
Hermans G, De Jonghe B, Bruyninckx F, Berghe GVd. Clinical review: Critical illness polyneuropathy and myopathy. Critical care. 2008;12(6):1-9.
Guarneri B, Bertolini G, Latronico N. Long-term outcome in patients with critical illness myopathy or neuropathy: the Italian multicentre CRIMYNE study. Journal of Neurology, Neurosurgery & Psychiatry. 2008;79(7):838-41.
Bolton CF. Neuromuscular manifestations of critical illness. Muscle & Nerve: Official Journal of the American Association of Electrodiagnostic Medicine. 2005;32(2):140-63.
Lacomis D, Zochodne DW, Bird SJ. Critical illness myopathy. Wiley Online Library; 2000. p. 1785-8.
